Clinical Trials Arena on MSN2d
AstraZeneca’s AZD0780 cuts LDL-C by 50% in Phase IIb trialAstraZeneca's AZD0780 has demonstrated significant efficacy in a Phase IIb trial, showing a 50.7% reduction in LDL-C after 12 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback